Tenalisib

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameTenalisib
Drug Alias Nametenalisib泰那利塞tenalisibum特那利司RP-6530 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors
TargetsPhosphatidylinositol 3 kinase deltaPhosphatidylinositol-4,5-Bisphosphate 3 kinase gamma
Therapy Area/IndicationsMetastatic breast cancerHematologic NeoplasmsTriple Negative Breast Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRhizen Pharmaceuticals Sa
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTongrun Bio-pharmaceutical (Shanghai) Co LtdRhizen Pharmaceuticals Sa
Inactive CompaniesCuron Biopharmaceutical (Australia) Co Pty Ltd
Active IndicationsMetastatic breast cancerHematologic NeoplasmsTriple Negative Breast Neoplasms +[6] 
Inactive IndicationsLymphoma, T-Cell, CutaneousLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 

Other Information

ATC CodeN/A
Related LinksN/A